Together, these results support our data that the targeting of p300 and CBP as a means of blocking ac-AR signaling is beneficial in prostate cancer; however, inhibition of HDACs is likely to promote AR acetylation, proving to be counter-effective for patients. Here, EP300 is linked to Familial prostate cancer.